Using symptom-based case predictions to identify host genetic factors that contribute to COVID-19 susceptibility by Lifelines COVID-19 Cohort Study et al.
RESEARCH ARTICLE
Using symptom-based case predictions to
identify host genetic factors that contribute to
COVID-19 susceptibility
Irene V. van BloklandID
1,2☯, Pauline LantingID
1☯, Anil P. S. Ori1,3☯, Judith M. VonkID
4☯,
Robert C. A. Warmerdam1☯, Johanna C. HerkertID
1, Floranne Boulogne1,
Annique ClaringbouldID
1,5, Esteban A. Lopera-Maya1, Meike Bartels6,7, Jouke-
Jan Hottenga6, Andrea Ganna8, Juha Karjalainen8,9,10, Lifelines COVID-19 cohort study¶,
The COVID-19 Host Genetics Initiative¶, Caroline Hayward11, Chloe Fawns-Ritchie12,
Archie Campbell13, David Porteous13, Elizabeth T. Cirulli14, Kelly M. Schiabor BarrettID
14,
Stephen Riffle14, Alexandre Bolze14, Simon White14, Francisco Tanudjaja14,
Xueqing Wang14, Jimmy M. Ramirez, III14, Yan Wei Lim14, James T. Lu14, Nicole
L. WashingtonID
14, Eco J. C. de Geus6,7, Patrick DeelenID
1,15, H. Marike Boezen4‡, Lude
H. Franke1‡*
1 Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The
Netherlands, 2 Department of Cardiology, University of Groningen, University Medical Center Groningen,
Groningen, The Netherlands, 3 Department of Psychiatry, University of Groningen, University Medical Center
Groningen, Groningen, The Netherlands, 4 Department of Epidemiology, University of Groningen, University
Medical Center Groningen, Groningen, The Netherlands, 5 Structural Computational Biology unit, EMBL,
Heidelberg, Germany, 6 Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam,
Amsterdam, The Netherlands, 7 Amsterdam Public Health research institute, Amsterdam UMC, Amsterdam,
The Netherlands, 8 Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland, 9 Broad
Institute of MIT and Harvard, Cambridge, MA, United States of America, 10 Analytic and Translational
Genetics Unit (ATGU), Massachusetts General Hospital, Boston, MA, United States of America, 11 MRC
Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh,
United Kingdom, 12 Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom,
13 Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and
Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom, 14 Helix OpCo LLC, San Mateo,
California, United States of America, 15 Department of Genetics, University Medical Centre Utrecht, Utrecht,
The Netherlands
☯ These authors contributed equally to this work.
‡ These authors are senior authorship on this work.




Epidemiological and genetic studies on COVID-19 are currently hindered by inconsistent
and limited testing policies to confirm SARS-CoV-2 infection. Recently, it was shown that it
is possible to predict COVID-19 cases using cross-sectional self-reported disease-related
symptoms. Here, we demonstrate that this COVID-19 prediction model has reasonable and
consistent performance across multiple independent cohorts and that our attempt to
improve upon this model did not result in improved predictions. Using the existing COVID-
19 prediction model, we then conducted a GWAS on the predicted phenotype using a total
of 1,865 predicted cases and 29,174 controls. While we did not find any common, large-
effect variants that reached genome-wide significance, we do observe suggestive genetic
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associations at two SNPs (rs11844522, p = 1.9x10-7; rs5798227, p = 2.2x10-7). Explorative
analyses furthermore suggest that genetic variants associated with other viral infectious dis-
eases do not overlap with COVID-19 susceptibility and that severity of COVID-19 may have
a different genetic architecture compared to COVID-19 susceptibility. This study represents
a first effort that uses a symptom-based predicted phenotype as a proxy for COVID-19 in
our pursuit of understanding the genetic susceptibility of the disease. We conclude that the
inclusion of symptom-based predicted cases could be a useful strategy in a scenario of lim-
ited testing, either during the current COVID-19 pandemic or any future viral outbreak.
Introduction
The Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome
Coronavirus-2 (SARS-CoV-2) has rapidly spread across the globe, posing a large burden on
individuals, healthcare systems, and societies as a whole. At the time of writing, more than 55
million infections and 1,300,000 deaths have been reported worldwide [1]. The symptoms and
disease severity of COVID-19 vary [2], ranging from asymptomatic or nonspecific symptoms
to severe illness with hospital admission and death. While the scientific community is rapidly
gaining more understanding of the pathophysiology of COVID-19 [3, 4], many questions
remain about the etiology of the disease and what factors are driving the interindividual vari-
ability in pathophysiology.
It is known that individual genetic differences in the human host contribute to immune
function and response to common infectious agents [5, 6]. Genome-wide association studies
(GWAS) have, for example, identified susceptibility loci for multiple common infections [7].
The identification of genetic factors can lead to new insights into disease mechanisms and help
improve vaccination strategies by optimizing vaccine-induced protection. For this reason, the
COVID-19 host genetics consortium (C19HG) was established to discover and study the
human genetic variants that modulate the susceptibility of developing COVID-19 symptoms
and COVID-19 severity [8]. However, the magnitude of the pandemic, limited testing capacity
and inconsistent testing policies have likely resulted in an underrepresentation of the number
of true cases. Using only confirmed cases reduces the power of any GWAS to detect associa-
tions and may be a source of bias.
Recently, a model was published that predicts the potential presence of COVID-19 based
on self-reported disease-related symptoms, which we will refer to as the Menni COVID-19
prediction model [9]. We investigated if potential COVID-19 predicted based on symptoms
can help accelerate the search for host genetic factors that contribute to the susceptibility of
developing COVID-19 symptoms, which we will refer to as COVID-19 susceptibility, and the
heterogeneity of COVID-19 severity. First, we confirmed that the Menni COVID-19 model
can identify cases with laboratory confirmed SARS-CoV-2 infection in three independent
cohorts. As existing COVID-19 prediction models used features not available in our cohorts,
we generated a COVID-19 prediction model optimized to the phenotypes described in our
cohorts. Second, as part of the C19HG consortium, we performed genetic analyses on pre-
dicted COVID-19 (1,865 cases and 29,174 controls, Fig 1) to search for host genetic factors
that contribute to COVID-19 susceptibility and explored possible downstream effects of the
loci identified. To assess the validity of the predicted COVID-19 phenotype, we compared
these results to the GWAS meta-analyses results based on confirmed COVID-19. We also
compared our findings to previously reported genetic associations with several viral infectious
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The Lifelines Biobank initiative has been made
possible by funding from the Dutch Ministry of
Health, Welfare and Sport; the Dutch Ministry of
Economic Affairs; the University Medical Center
Groningen (UMCG the Netherlands); the University
of Groningen and the Northern Provinces of the
diseases to look for genetic factors shared between COVID-19 susceptibility and other viral
infectious diseases.
Materials and methods
Data collection and preparation
Four separate cohorts contributed data to the presented analysis.
The Lifelines COVID-19 cohort consists of individuals from the Lifelines population cohort
and the Lifelines NEXT birth cohort in the Northern part of the Netherlands [10]. Within the
Lifelines COVID-19 cohort, questionnaires were sent out to participants over the age of 18
years via email on a weekly basis starting March 30, 2020. Items about COVID-19 infection
and perceived symptoms, drug use, mental health and vaccination status were questioned
weekly. A comprehensive cohort description has been described previously [11].
The Helix cohort consists of individuals from the Helix DNA Discovery Project, an unse-
lected population of adults from across the United States [12]. COVID-19 questionnaires were
emailed to participants in April and May of 2020. The questionnaire format was based on
example surveys and suggested symptoms and pertinent information compiled by the C19HG
[13].
The Netherlands Twin Register (NTR) consists of members of twin families that had been
registered as willing to participate in survey, biobank and experimental research. NTR partici-
pants aged 16 years or older (range 16–95) received an online questionnaire at the end of April
(wave 1) or the middle of May (wave 2). The questionnaire was modelled on the Lifelines sur-
vey and contained items about COVID-19 testing, diagnosis and treatment of COVID-19, per-
ceived flu-like symptoms, drug use, past and present chronic diseases, household composition,
work setting and the impact of the corona crisis on their mental health and lifestyle
behaviours.
The Generation Scotland cohort consists of individuals over the age of 18 from the Genera-
tion Scotland biobank. The Covid Life survey was initially launched on April 17, 2020 with a
few hundred individuals to make sure the survey process was working well. The following
week, the survey was rolled out by email and letter to all of the current Generation Scotland
volunteers. Volunteers were asked questions about the impact the pandemic had on their life
and included questions on education, mental health, wellbeing and more.
Ethics statement
Generation Scotland received ethical permission for the creation of the GS:SFHS study (05/
S1401/89 Tayside Committee on Medical Research Ethics A). Generic Research Tissue Bank
approval has been granted for use of the resource. (20/ES/0021 East of Scotland Research Eth-
ics Service). All participants signed an informed consent form prior to enrolment.
Helix data were collected under Western IRB Protocol #20170748. All participants signed
an informed consent form prior to enrolment.
The Lifelines study was approved by the ethics committee of the University Medical Center
Groningen, document number METc2007/152. All participants signed an informed consent
form prior to enrolment.
The NTR study was approved by the ethics committee of the Faculty of Behavioural and
Movement Sciences, Vrije Universiteit Amsterdam, reference: VCWE-2020-083. All partici-
pants signed an informed consent form prior to enrolment.
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The Menni COVID-19 prediction model
The predictive properties of the Menni COVID-19 prediction model were investigated in the
Helix, Lifelines, and NTR cohorts separately. The Generation Scotland cohort could not be
Fig 1. Overview of the main analysis.
https://doi.org/10.1371/journal.pone.0255402.g001
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included in this analysis since self-reported SARS-CoV-2 reverse-transcription PCR
(RT-PCR) test outcomes were not available. In the three cohorts with RT-PCR test outcomes
available, symptoms that best captured the included symptoms in the Menni COVID-19 pre-
diction model were selected and non-binary answers (5- or 7-point Likert scale answers) were
recoded into binary responses using cut-off values as presented in S1 Table. We applied the
Menni COVID-19 prediction model (i.e. predicted COVID-19 score = -1.32 –(0.01 � age) +
(0.44 � male sex) + (1.75 � loss of smell and taste) + (0.31 � severe or significant persistent
cough) + (0.49 � severe fatigue) + (0.39 � skipped meals)) and calculated the predicted proba-
bility of COVID-19 according to exp(predicted COVID-19 score)/(1+exp(predicted COVID-
19 score)). The predictive properties of the model were tested using an ROC analysis by com-
paring the predicted probability of COVID-19 to the self-reported SARS-CoV-2 reverse-tran-
scription PCR (RT-PCR) test outcome. Sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) were calculated based on a predicted probability higher
than 0.50 to define a positive predicted case.
Attempt to improve the Menni COVID-19 prediction model
The three cohorts with self-reported SARS-CoV-2 reverse-transcription PCR (RT-PCR) test
outcomes available (Helix, Lifelines and NTR) were used in an attempt to improve the Menni
COVID-19 prediction model. Self-reported symptoms that were present in all three cohorts
were used. Symptoms were reported on a 5-point or 7-point Likert-scale (Lifelines COVID-19
and NTR cohorts) and binary scale (Helix cohort). To categorize all symptoms into a binary
variable, we assessed the appropriate cut-off values in the Lifelines COVID-19 cohort for each
self-reported symptom by performing a logistic regression on subjects with a positive test out-
come (n = 56) compared to subjects with a negative test outcome (n = 586). In these models,
each symptom was investigated separately by using two dummy variables indicating symptom
severity (low and intermediate/high) with the reference being the absence of the symptom. If
only intermediate/high symptom severity was significantly associated with a positive test, we
used this value as cut-off. If both low and intermediate/high symptom severity were significant,
we used low symptom severity as cut-off.
The symptoms selected for this model had to be present for the entire data-collection period
in all three cohorts, resulting in the following symptoms being selected: coughing-any, diar-
rhea/stomach ache, difficulty breathing, fever, loss of smell/taste, runny nose, sore throat and
tired-any. Subsequently, we performed forward and backward stepwise logistic regression in
the Lifelines COVID-19 Cohort to construct the model most predictive for a positive test out-
come (p-in = 0.10 and p-out = 0.10). The predictive properties were tested using an ROC anal-
ysis. Sensitivity, specificity, PPV and NPV were calculated based on the predicted probability,
favouring an optimal PPV. We then applied this model to the Helix and NTR cohorts and
tested the predictive properties.
Genome-wide association analysis
To investigate whether the predicted COVID-19 phenotype can help accelerate the search for
host genetic factors that contribute to the susceptibility of developing COVID-19 symptoms,
we performed a GWAS for predicted COVID-19 case-control status as part of the COVID-19
Host Genetics Initiative (C19HG) with a total of 1865 cases and 29174 controls (https://www.
covid19hg.org/results/, release 3). All cohorts consist of individuals of European ancestry. See
S2 Table for the full phenotype description and detailed analysis plan. Additional details on
cohort level GWAS and C19HG meta-analysis are provided in the S1 Methods.
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Processing of GWAS results
We downloaded the third release of the results of the predicted COVID-19 meta-analysis
(Predicted COVID-19 from self-reported symptoms vs. predicted or self-reported non-COVID-
19) from the C19HG website (https://www.covid19hg.org/results/) (genome assembly
GRCh37, retrieved on 02-07-2020). For a comparison with other COVID-19 phenotypes we
downloaded meta-analyses for hospitalized COVID-19 vs. population, COVID-19 vs. self-
reported negative, and COVID-19 vs. population as well. For these downloaded summary sta-
tistics, we added RSIDs where both the genomic location and alleles matched to a variant
from dbSNP [14]. Variants were filtered on MAF > 0.01 (based on the aggregated allele fre-
quency over all cohorts), after which we performed p-value informed LD pruning, also
called clumping, using PLINK (v1.90b6.10 64-bit) [15, 16] and the European population
from the 1000 Genomes Project (phase 3) as a reference panel [17]. For clumping, thresholds
on the linkage disequilibrium and genomic distance were set to an R2 of 0.2 and a distance
of 250 kb respectively. In GWASs other than the predicted COVID-19 analysis, the maxi-
mum p-value of index variants was set to 5x10-8. All other parameters were left as their
default values.
Comparison between predicted COVID-19 and three other GWASs
For the predicted COVID-19 GWAS, the top 20 independent SNPs were selected, and these
SNPs were compared with their respective effects in other COVID-19 GWASs to determine if
their effects replicated. The same was done using the independent genome-wide significant
hits from each of the other COVID-19 GWASs.
Comparison of COVID-19 GWASs with previously reported associations
in viral infection phenotypes
First, genome-wide significant variants (P� 5x10-8) were selected for eight viral infection phe-
notypes from the NHGRI-EBI GWAS Catalog (accessed July 7, 2020) [18]. Next, the individual
SNPs corresponding to each association were queried from the processed COVID-19 GWASs.
For every viral infection SNP that we found in one of the four COVID-19 GWASs, we deter-
mined if the SNP replicated, dictated by the p-value of the association in the respective
COVID-19 GWAS, the Bonferroni-corrected significance level calculated from the number of
SNPs for a viral infection trait and an a priori Bonferroni adjusted alpha of 0.05.
To get a more concrete indication whether or not the COVID-19 GWASs showed an
increased signal of previously reported viral infection associations, quantile-quantile plots
were made and accompanying genomic inflation factors (λ) were calculated in the selection of
SNPs that have previously been reported to be associated with the various viral infection traits.
A significance value for every λ was calculated by simulating 1000 expected λ-values, calculat-
ing the consequent Z-score for the observed λ, and determining a two-tailed p-value. λ-values
were simulated by sampling n values from a χ2-distribution (k = 1), where n corresponds to
the number of p-values used to calculate the observed λ-value.
Enrichment analysis
Within the predicted COVID-19 phenotype, we selected all variants with a p-value� 5x10-4
and used DEPICT [19] with default settings to search for enrichment in pathways and protein-
protein interactions. We used a false discovery rate of 0.05.
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Results
Description of cohorts
The Generation Scotland, Helix, Lifelines and Netherlands Twin Register (NTR) cohorts
include a total of 168 (0, 27, 56 and 85, respectively) positively tested COVID-19 cases and
1157 (0, 189, 586 and 382, respectively) negatively tested controls. Descriptive statistics of the
cohorts are provided in S3 Table. Additional results comparing positive and negatively tested
individuals in Lifelines are presented in the S1 Results.
Replication of the Menni COVID-19 prediction model in Helix, Lifelines
and NTR
Table 1 presents the model diagnostics of the replication of the Menni COVID-19 prediction
model in the three independent cohorts. The Menni model yields an area under the curve
(AUC) ranging between 0.79 and 0.86 across the three cohorts, similar to the performance
reported in the original study. Associations between predicted COVID-19 and the presence of
specific co-morbidities in Lifelines are presented in the S1 Results.
A new Lifelines prediction model for COVID-19 yields similar
performance
Using self-reported symptoms of 56 positive and 586 negative test outcome cases in the Life-
lines cohort, we next attempted to improve on the Menni COVID-19 prediction model. The
results of the logistic regression used to determine the optimal cut-off values to recode the
symptoms into binary variables are presented in S4 Table. The best prediction model was:
-4.497 + 1.032 × cough + 2.042 × fever + 2.145 × loss of smell or taste. The estimates of the
model and the predicted probability cut-off used to define a positive predicted case are pre-
sented in S5a and S5b Table. S5c Table shows the diagnostics of this Lifelines model in all 3
cohorts. Overall, the prediction accuracies of the two models are comparable. As the Menni
COVID-19 prediction model was developed and validated in two larger cohorts, we decided to
continue with case prediction based on the Menni COVID-19 prediction model in the subse-
quent GWAS.
The first GWAS of predicted COVID-19
We conducted a GWAS meta-analysis on 1,865 predicted cases and 29,174 controls across
four independent cohorts. The full summary statistics of our analysis are available for down-
load online on the C19HG website [8]. The results of the top 20 (P < 5.1x10-6) independent
single nucleotide polymorphisms (SNPs) for predicted COVID-19 are shown in Fig 2. Sugges-
tive evidence of association with predicted COVID-19 was found for two SNPs (rs11844522,
p = 1.9x10-7; rs5798227, p = 2.2x10-7) (S1 Fig).
Table 1. Model diagnostics of the Menni COVID-19 prediction model in Helix, Lifelines and NTR.
Cohort AUC (95% CI)a Sensitivity Specificity Positive predictive value Negative predictive value
Helix 0.79 (0.725–0.869) 0.481 0.905 0.419 0.924
Lifelines 0.824 (0.758–0.890) 0.446 0.951 0.463 0.947
NTR 0.864 (0.822–0.905) 0.415 0.936 0.596 0.876
aThe model: -1.32–0.01�age + 0.44�male sex + 1.75�loss of smell or taste + 0.31�severe or significant persistent cough + 0.49�severe fatigue + 0.39�skipped meals. A
predicted probability cut-off of > 0.50 is used to define a positive predicted case.
https://doi.org/10.1371/journal.pone.0255402.t001
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A comparison of the top 20 SNPs for predicted COVID-19 (Predicted COVID-19 from self-
reported symptoms vs. predicted or self-reported non-COVID-19) with three other COVID-19
phenotypes showed three SNPs to be associated with the same direction of effect (rs13288295
in COVID-19 vs. self-reported negative, rs75517918 in COVID-19 vs. population and
rs143825287 in both of these two phenotypes) and one SNP to be associated with the opposite
direction of effect (rs11844522 in Hospitalized COVID-19 vs. population), based on a p-value
threshold of 0.05 (Fig 2).
The meta-analyses of the COVID-19 vs. population GWAS showed an independent
genome-wide significant association on locus 3p21.31 (rs35652899, p = 9.5x10-11). The hospi-
talized COVID-19 vs. population GWAS also showed two approximately independent
genome-wide significant associations, of which the most significant is in high linkage disequi-
librium with the associated variant from the COVID-19 vs. population analysis (rs35044562,
p = 3.1x10-15, R2 = 0.97). A comparison of these results to the predicted COVID-19 GWAS
showed that both these associations with closely linked variants did not replicate at a signifi-
cance level of 0.05 (p-values 0.18 and 0.22, respectively).
Fig 2. Overview of the top loci associated with predicted COVID-19. Shown are the effect size estimates of the top 20 independent SNPs associated
with predicted COVID-19 and each of their associations with COVID-19 vs. self-reported negative, COVID-19 vs. population and Hospitalized
COVID-19 vs. population. The effect sizes are shown with the risk allele odds ratio (OR) on a log-scale with a corresponding 95% confidence interval
(CI). Colours indicate various p-value thresholds as described in the figure legend.
https://doi.org/10.1371/journal.pone.0255402.g002
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Next, we examined whether previously reported genetic associations with common viral
infections share any overlap with the variants identified by our GWAS on COVID-19 suscepti-
bility. After querying the NHGRI-EBI GWAS Catalog, we further investigated 270 genome-
wide significant SNPs associated with known viral infections. Here we observe no major over-
lap with predicted COVID-19 at the level of individual SNPs (a priori Bonferroni-adjusted
alpha = 0.05, S2 Fig). Out of 270 tested genome-wide significant SNPs, five replicate in one of
the assessed COVID-19 phenotypes. Of these five variants, we found only a single variant to
replicate in the predicted COVID-19 phenotype (rs3806400, p = 3.077x10-4). Furthermore,
there was no overall increase in genomic inflation (λ) when considering all 270 SNPs jointly
for any of the four GWAS phenotypes (λ = 0.815, p = 0.2 for predicted COVID-19, λ = 1.234,
p = 0.1 for COVID-19 vs. self-reported negative, λ = 1.110, p = 0.5 for COVID-19 vs. popula-
tion, λ = 0.780, p = 0.1 for hospitalized COVID-19 vs. population, respectively) (S3 Fig).
Downstream analysis using DEPICT [19] ascertained that protein-protein interactions
with the solute carrier family 25 member 6 gene (SLC25A6) are significantly enriched
(p = 8.6x10-6). Full results are provided in S6 Table.
Discussion
We investigated if symptom-based prediction of potential COVID-19 cases can aid in the
search for host genetic factors that contribute to COVID-19 susceptibility. We confirm that
self-reported disease-related symptoms are useful for the prediction of infection status and
report the first genome-wide association analysis on predicted COVID-19 in the C19HG con-
sortium. We find suggestive evidence for rs11844522 and rs5798227 to be associated with pre-
dicted COVID-19 and observe no evidence for overlap with known genetic associations with
other viral infections.
While the Menni prediction model has reasonable predictive properties, with AUCs rang-
ing between 0.74 and 0.86 in the included cohorts, it yielded lower sensitivities (0.42 to 0.48)
and positive predictive values (0.42 to 0.60). This indicates that a significant proportion of
COVID-19 cases will be missed by the prediction model (false negatives) and that positive pre-
dicted cases will include false positives. As our attempt to improve this model did not result in
improved predictions, this remains an avenue to explore for future work. Symptom prevalence
before and after testing in Lifelines suggests that repeated self-report assessments of disease-
related symptoms may offer finer resolution to further increase prediction accuracy.
The predicted COVID-19 phenotype can help increase the number of cases for genetic
analyses of COVID-19. While GWASs can benefit from larger sample sizes, caution should be
taken when applying more loose phenotyping, as such an approach can produce a smaller and
less-specific genetic signal [20]. The predicted positive COVID-19 cases could include false
positive cases that have underlying conditions, such as other viral infections or common dis-
eases, that share symptomatology with the symptoms included in the prediction model. This
may have subsequently confounded our GWAS, yielding results that are less specific for
COVID-19 and more related to genetic susceptibility to general immune defence or potentially
even conditions un-related to COVID-19. Out of the 270 genome-wide significant variants
associated with other infectious diseases, only one variant replicated in the predicted COVID-
19 phenotype (rs3806400, p = 3.077x10-4). Additionally, the calculated genomic inflation fac-
tors showed no inflation for viral infection SNPs across any of the four COVID-19 phenotypes.
Based on these first results, we conclude there is minimal overlap between the genetic predis-
position of COVID-19 and other infectious diseases.
The outcomes of the GWAS meta-analysis of predicted COVID-19 showed suggestive asso-
ciation for the SNPs rs11844522 and rs5798227. Interestingly, rs11844522 is in a locus
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comprising immunoglobulins, and the closest mapping gene (IGHV3-7) to rs11844522 is part
of a gene family that is enriched in total VDJ expression of COVID-19 patients in single-cell
transcriptomic data [21]. Rs11844522 replicated with an opposite direction of effect in the hos-
pitalized COVID-19 vs. population phenotype, and this is likely explained by the difference in
phenotype of that GWAS meta-analysis, which focused on COVID-19 severity (i.e. susceptibil-
ity to a poor outcome) rather than COVID-19 susceptibility (i.e. susceptibility to developing
COVID-19 symptoms). The lack of genome-wide significant SNPs in our predicted COVID-
19 GWAS could be due to the smaller sample size. Among the 20 most-significant top-vari-
ants, we observe three variants with a nominal significant genetic association signal (at
p< 0.05) in the meta-analyses on the COVID-19 vs. population or the COVID-19 vs. self-
reported negative phenotypes, all with the same direction of effect.
A comparison between COVID-19 GWASs showed that the GWAS on predicted COVID-
19 was unable to replicate the top genome-wide significant hit of the GWAS on positively
tested COVID-19 cases vs. the general population (COVID-19 vs. population). Interestingly, a
closely linked variant in the analysis that considers COVID-19 severity (hospitalized COVID-
19 vs. population), is even more significant than the top variant in COVID-19 vs. population
(rs35044562: p = 3.1x10-15 and rs35652899: p = 8.6x10-10, respectively, R2 = 0.97). In the latter
analysis, only the COVID19-Host(a)ge cohort, which contributed the largest number of cases,
showed a genome-wide significant association with the top variant at this locus (p = 8.2x10-11),
while other cohorts all showed much less significance (UK Biobank: p = 1.3x10-3; other
cohorts: p> 0.01). Looking into this discrepancy revealed that the COVID19-Host(a)ge cohort
focusses on severe COVID-19 patients, which is indicated by the fact that the cases contributed
by this cohort to the COVID-19 vs. population GWAS completely overlap with hospitalized
cases contributed to the GWAS on COVID-19 severity. A similar observation can be made for
the UK Biobank, for which the number of hospitalized cases contributed to the hospitalized
COVID-19 vs. population analysis constitute 66% of cases in COVID-19 vs. population, an
observation that explains the increased significance for the association in this cohort compared
to others. Taking these observations into account, it seems reasonable to assume that the
reported variants on the 3p21.31 locus are more likely to be associated with COVID-19 sever-
ity than COVID-19 susceptibility. Therefore, no conclusion can be made on the performance
of the predicted COVID-19 phenotype as a proxy for COVID-19 susceptibility based solely on
the absence of an association with the 3p21.31 locus.
Downstream DEPICT analysis of the GWAS outcomes identified a significant enrichment
of protein-protein interactions with SLC25A6. This gene encodes adenine nucleotide translo-
cator 3 (ANT3), which is a core component of the mitochondrial permeability transition pore
(MPTP) and is involved in apoptosis. SLC25A6 is downregulated in human cytomegalovirus
infection and associated with influenza virus–induced apoptosis [22, 23]. This indicates this
gene might also be relevant to COVID-19 susceptibility.
Limitations
There are multiple limitations of using predicted COVID-19 cases that we need to consider.
Firstly, the training data might not be fully representative of the whole spectrum of COVID-19
symptoms since testing of putative cases in the early months of the pandemic was mostly
restricted to patients with a more severe phenotype. Individuals with essential occupations, for
example healthcare professionals, were also more frequently tested at the beginning of the pan-
demic. Secondly, some symptoms are also present in common chronic diseases, for example
“loss of smell and taste” is frequent among patients with a neurological disorder. Indeed, a pre-
liminary analysis of the Lifelines data showed enrichment of patients with pre-existing
PLOS ONE GWAS for symptom-based predicted COVID-19
PLOS ONE | https://doi.org/10.1371/journal.pone.0255402 August 11, 2021 10 / 18
conditions in the predicted COVID-19 cases as compared to controls but no enrichment in
the confirmed COVID-19 cases compared to confirmed negative cases, indicating that these
individuals might be incorrectly predicted as COVID-19 cases by the Menni COVID-19 pre-
diction model based on their symptoms (S4 Fig). Thirdly, the prevalence of COVID-19 might
be different among different populations and cohorts. The false positive rates of the prediction
models are likely to be larger if the prevalence of COVID-19 is small compared to other infec-
tious diseases that often have similar symptoms.
Conclusions
In an effort to identify host genetic factors that contribute to the susceptibility of COVID-19,
we have conducted a GWAS on symptom-based prediction of COVID-19. While we demon-
strated that the Menni et al. COVID-19 prediction model has reasonable and consistent per-
formance across multiple independent cohorts, the GWAS on the predicted phenotype did
not yield genome-wide significant loci. Explorative analyses of the genetic overlap between
predicted COVID-19 and other viral infectious diseases, suggest that genetic variants involved
in other viral infectious diseases do not overlap with COVID-19 susceptibility and that
COVID-19 severity may have a partially different underlying genetic architecture. Our study
shows that the inclusion of symptom-based predicted cases could be a useful strategy in a sce-
nario of limited testing, either during the current COVID-19 pandemic or any future viral
outbreak.
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